Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,600

Employees17,600

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,600

Employees17,600

GILD Key Statistics

Market cap

150.08B

Market cap150.08B

Price-Earnings ratio

24.06

Price-Earnings ratio24.06

Dividend yield

2.60%

Dividend yield2.60%

Average volume

6.78M

Average volume6.78M

High today

$121.15

High today$121.15

Low today

$118.71

Low today$118.71

Open price

$120.68

Open price$120.68

Volume

5.31M

Volume5.31M

52 Week high

$124.61

52 Week high$124.61

52 Week low

$86.08

52 Week low$86.08

GILD News

Nasdaq 2d

Validea Detailed Fundamental Analysis - GILD

Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our P/B Growth Invest...

Seeking Alpha 4d

Gilead discontinues early-stage trial for long-acting injectable for HIV

Gilead Sciences (NASDAQ:GILD) has discontinued a Phase 1 trial for GS-1219, a long-acting subcutaneously delivered treatment targeting HIV infections, according...

TipRanks 4d

Gilead terminated Phase 1 study of ‘1219, says RBC Capital

RBC Capital reports that newly updated clinicaltrials.gov records show that Gilead’s (GILD) Phase 1 study testing ‘1219, a next-generation longer-acting injecta...

Analyst ratings

70%

of 30 ratings

Buy

70%

Hold

30%

Sell

More GILD News

Simply Wall St 6d

Gilead Sciences: Assessing Valuation After Major Trodelvy Breast Cancer Breakthrough and HIV Advances

Gilead Sciences (GILD) has been drawing attention after releasing promising Phase 3 results for Trodelvy. The results show a marked extension in progression-fre...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.